“Appropriate” Defibrillator, Drug-Eluting Stent Payments Pondered By CMS
This article was originally published in The Gray Sheet
Executive Summary
CMS is seeking comments on ways to structure inpatient payment for implantable cardiac defibrillators so that clinicians will consider using less sophisticated devices in clinically appropriate situations
You may also be interested in...
Boston Scientific, J&J Analyses Aim To Convince CMS To Raise DES Payments
Boston Scientific and J&J are providing additional external data analyses to counter CMS' claim that more evidence is required to justify altering the drug-eluting stent diagnosis-related groups (DRGs)
Boston Scientific, J&J Analyses Aim To Convince CMS To Raise DES Payments
Boston Scientific and J&J are providing additional external data analyses to counter CMS' claim that more evidence is required to justify altering the drug-eluting stent diagnosis-related groups (DRGs)
AdvaMed Urges Defibrillator, Carotid Stent, DES Payment Policy Changes
CMS' efforts to "interject debate" over expanded national coverage of defibrillators into the payment realm by soliciting ways to encourage less expensive use of ICDs when clinically valid are inappropriate, AdvaMed says